Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. Vertex is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad clinical pipeline in kidney disease, neuropathic pain, type 1 diabetes and myotonic dystrophy type 1. Its SEC filings give investors and analysts detailed insight into financial performance, risk factors and material events affecting the business.
Recent Form 8-K filings from Vertex have reported quarterly financial results and related guidance under Item 2.02, Results of Operations and Financial Condition. These filings typically reference accompanying press releases that summarize revenue trends, research and development spending and updates across the company’s portfolio, including CFTR modulators such as ALYFTREK and TRIKAFTA, CASGEVY gene-edited cell therapy and JOURNAVX for acute pain. Other 8-K items may address changes in key executives or other corporate developments when they occur.
On Stock Titan, Vertex filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the main points of lengthy documents, so users can quickly understand how new information may relate to VRTX stock without reading every page. For example, AI summaries can highlight key themes in earnings-related 8-Ks, note significant changes in guidance or spending, and point out disclosures related to the progress of pivotal trials or regulatory submissions.
In addition to 8-Ks, users can review Vertex’s annual and quarterly reports when available, as well as any proxy materials and registration statements that may be filed. AI analysis tools on Stock Titan can surface trends across multiple filings, making it easier to track how Vertex’s financial profile and pipeline narrative evolve over time. This page is a useful starting point for anyone researching VRTX from a regulatory and disclosure perspective, complementing price charts, news and other fundamental data.
Vertex Pharmaceuticals executive Mark E. Bunnage has filed an initial insider ownership report. As of February 1, 2026, he beneficially owns 16,062 shares of Vertex common stock, held directly. He serves as EVP, Chief Scientific Officer and reports no derivative securities in this filing.
Vertex Pharmaceuticals executive Charles F. Wagner Jr., EVP, CO & FO, reported the acquisition of 13,600 shares of Vertex common stock through earned performance awards. On 01/22/2026, he received 9,440 shares tied to a performance stock unit award granted on 02/01/2023 and 4,160 shares from a performance stock unit award granted on 02/12/2025, both at a price of $0 per share.
The company’s management development and compensation committee certified the performance-goal attainment on 01/22/2026. The 2023 award shares will vest on 02/13/2026, while the 2025 award shares will vest in installments beginning on 02/24/2026. Following these transactions, Wagner directly holds 51,325 shares of Vertex common stock.
Vertex Pharmaceuticals executive Ourania Tatsis reported awards of company stock tied to performance goals. On January 22, 2026, she acquired 7,866 shares of Vertex common stock at $0 per share as earned performance shares from a performance stock unit award originally granted on February 1, 2023. On the same date, she also acquired 3,883 shares at $0 per share as earned performance shares from a separate performance stock unit award granted on February 12, 2025. These awards were triggered after the company’s management development and compensation committee certified that the required performance goals had been met, with the 2023 grant scheduled to vest on February 13, 2026 and the 2025 grant scheduled to vest in installments beginning on February 24, 2026. Following these transactions, Tatsis directly beneficially owned 54,042 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev reported new stock awards tied to performance goals. On 01/22/2026, he acquired 7,866 shares of Vertex common stock and another 3,883 shares at a price of $0 per share, reflecting earned performance stock unit awards granted on 02/01/2023 and 02/12/2025 after the compensation committee certified goal attainment on 01/22/2026. Following these awards, he directly holds 70,998 common shares, with additional indirect holdings of 882 shares in a 401(k) plan and 9,301 shares held in trust. The earned performance shares are scheduled to vest on 02/13/2026 and in installments beginning on 02/24/2026.
Vertex Pharmaceuticals executive McKechnie Duncan reported stock awards tied to performance goals. On 01/22/2026, Duncan acquired 4,720 shares of Vertex common stock at a price of $0 following the earning of performance shares from a performance stock unit award granted on 02/01/2023. After this transaction, Duncan directly owned 20,858 shares of common stock.
On the same date, Duncan also acquired 2,080 additional shares of Vertex common stock at a price of $0, representing earned performance shares from a performance stock unit award granted on 02/12/2025, bringing direct ownership to 22,938 shares. The issuer's management development and compensation committee certified the level of performance-goal attainment on 01/22/2026. The shares from the 2023 award will vest on 02/13/2026, and the shares from the 2025 award will vest in installments beginning on 02/24/2026.
Vertex Pharmaceuticals Executive Chairman Jeffrey M. Leiden reported the grant of 9,012 shares of common stock on January 22, 2026. The shares were acquired at a price of $0 as earned performance shares from a performance stock unit award originally granted on February 12, 2025, which was subject to performance-vesting conditions.
The company’s management development and compensation committee certified the level of performance-goal attainment on January 22, 2026, and these shares are scheduled to vest on February 24, 2026. Following this grant, Leiden beneficially owns 33,039 shares of Vertex common stock directly, plus 440 additional shares held indirectly through a 401(k) plan.
Vertex Pharmaceuticals CEO and President Reshma Kewalramani reported two stock acquisitions tied to performance awards. On 01/22/2026, she acquired 26,972 shares of common stock at $0, representing earned performance shares from a performance stock unit award granted on 02/01/2023 after the compensation committee certified performance-goal attainment. These shares will vest on 02/13/2026, bringing her direct holdings to 142,940 shares.
On the same date, she acquired 11,885 additional common shares at $0 as earned performance shares from a separate performance stock unit award granted on 02/12/2025, also following committee certification of performance-goal attainment. These shares will vest in installments beginning on 02/24/2026, increasing her directly held common stock to 154,825 shares.
Vertex Pharmaceuticals executive Carmen Bozic reported stock awards tied to prior performance-based grants. On 01/22/2026 she acquired 7,866 shares of common stock at $0, increasing her directly held stake to 40,535 shares. On the same date she acquired an additional 3,467 common shares at $0, bringing her directly held total to 44,002 shares.
The first block of 7,866 shares represents earned performance shares from a performance stock unit award granted on 02/01/2023, with shares scheduled to vest on 02/13/2026. The 3,467 shares represent earned performance shares from a performance stock unit award granted on 02/12/2025, with shares scheduled to vest in installments beginning on 02/24/2026.
Vertex Pharmaceuticals executive Jonathan Biller reported the acquisition of 9,068 shares of common stock through earned performance awards. On 01/22/2026, he received 6,294 shares tied to a performance stock unit grant from 02/01/2023 and 2,774 shares tied to a grant from 02/12/2025, both at a price of $0 per share. The company’s management development and compensation committee certified performance attainment on 01/22/2026. The first block of shares is scheduled to vest on 02/13/2026, and the second will vest in installments beginning on 02/24/2026. Following these awards, Biller directly beneficially owns 24,374 shares of Vertex common stock.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported the vesting of performance-based stock awards. On January 22, 2026, he acquired 3,934 shares of Vertex common stock tied to a performance stock unit grant from February 1, 2023, and 3,883 shares tied to a performance stock unit grant from February 12, 2025, both at a price of $0 per share as earned performance shares.
The compensation committee certified achievement of the performance goals on January 22, 2026. The shares from the 2023 grant are scheduled to vest on February 13, 2026, while the 2025 grant will vest in installments beginning on February 24, 2026. Following these transactions, Atkinson directly holds 24,669 shares of Vertex common stock.